RGNX
Price:
$7.465
Market Cap:
$369.85M
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II;RGX-111, which is in Phase I/II clinical trial for...[Read more]
Industry
Biotechnology
IPO Date
2015-09-17
Stock Exchange
NASDAQ
Ticker
RGNX
According to REGENXBIO Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 397.30M. This represents a change of -48.87% compared to the average of 777.06M of the last 4 quarters.
The mean historical Enterprise Value of REGENXBIO Inc. over the last ten years is 919.30M. The current 397.30M Enterprise Value has changed 4.22% with respect to the historical average. Over the past ten years (40 quarters), RGNX's Enterprise Value was at its highest in in the September 2018 quarter at 2.41B. The Enterprise Value was at its lowest in in the September 2015 quarter at -99381730.00.
Average
919.30M
Median
961.44M
Minimum
98.16M
Maximum
1.47B
Discovering the peaks and valleys of REGENXBIO Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 373.78%
Maximum Annual Enterprise Value = 1.47B
Minimum Annual Increase = -75.56%
Minimum Annual Enterprise Value = 98.16M
Year | Enterprise Value | Change |
---|---|---|
2023 | 839.79M | -14.00% |
2022 | 976.53M | -13.52% |
2021 | 1.13B | -20.77% |
2020 | 1.43B | -1.36% |
2019 | 1.44B | -1.43% |
2018 | 1.47B | 54.91% |
2017 | 946.35M | 103.50% |
2016 | 465.05M | 373.78% |
2015 | 98.16M | -75.56% |
2014 | 401.67M | 0.44% |
The current Enterprise Value of REGENXBIO Inc. (RGNX) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
981.84M
5-year avg
1.16B
10-year avg
919.30M
REGENXBIO Inc.’s Enterprise Value is less than Day One Biopharmaceuticals, Inc. (851.52M), less than Replimune Group, Inc. (907.78M), less than Mirum Pharmaceuticals, Inc. (2.12B), less than Rocket Pharmaceuticals, Inc. (1.22B), less than Avidity Biosciences, Inc. (3.36B), less than uniQure N.V. (661.42M), less than Protagonist Therapeutics, Inc. (2.23B), less than Pliant Therapeutics, Inc. (796.64M), less than Immunocore Holdings plc (1.36B), less than Revolution Medicines, Inc. (7.95B), greater than Monte Rosa Therapeutics, Inc. (351.56M), less than Stoke Therapeutics, Inc. (450.28M), greater than AN2 Therapeutics, Inc. (7.28M), greater than Passage Bio, Inc. (33.88M), greater than 4D Molecular Therapeutics, Inc. (107.26M), less than Crinetics Pharmaceuticals, Inc. (4.72B), greater than LianBio (-66141903.00), greater than Kezar Life Sciences, Inc. (29.11M),
Company | Enterprise Value | Market cap |
---|---|---|
851.52M | $1.27B | |
907.78M | $945.15M | |
2.12B | $2.03B | |
1.22B | $1.26B | |
3.36B | $3.73B | |
661.42M | $845.45M | |
2.23B | $2.35B | |
796.64M | $816.05M | |
1.36B | $1.41B | |
7.95B | $8.06B | |
351.56M | $433.44M | |
450.28M | $598.00M | |
7.28M | $40.78M | |
33.88M | $40.35M | |
107.26M | $269.97M | |
4.72B | $4.99B | |
-66141903.00 | $34.47M | |
29.11M | $47.06M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like REGENXBIO Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like REGENXBIO Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is REGENXBIO Inc.'s Enterprise Value?
What is the highest Enterprise Value for REGENXBIO Inc. (RGNX)?
What is the 3-year average Enterprise Value for REGENXBIO Inc. (RGNX)?
What is the 5-year average Enterprise Value for REGENXBIO Inc. (RGNX)?
How does the current Enterprise Value for REGENXBIO Inc. (RGNX) compare to its historical average?